Abstract
Alzheimer disease (AD) includes inflammatory processes in the senile plaques and surrounding glia, with increased expression of acute phase proteins such as C-reactive protein (CRP) and IL-6. Increased IL-6 expression during normal brain aging suggests a link of age-related inflammation to the onset of AD during aging. Blood levels of CRP and IL-6 are also associated with higher risk of Alzheimer disease and cognitive decline during aging. Some infections are known to induce inflammation and amyloid deposits. For example, HIV induces the deposition of the same beta-amyloid as in Alzheimer disease. The ApoE4 allele may increase HIV-associated dementia, in addition to its well-known effect on accelerating the onset age of AD. Many other adverse effects of apoE4 are recognized, which suggested the hypothesis that apoE4 persists in human populations because of balancing selection (Charlesworth-Martin hypothesis). The apoE4 allele was acquired during human evolution and may have conferred initial advantages in pathogen resistance. As evidence for this hypothesis, apoE4 carriers have less severe liver damage during hepatitis C infections. As human lifespan lengthened and cognitive and cardiovascular health became more important, the apoE3 allele spread, while the E4 allele was maintained in all populations by balancing selection.
Keywords: Alzheimer, aging, apoE, evolution, amyloid, infection, inflammation, CRP, IL-6
Current Alzheimer Research
Title: Systemic Inflammation, Infection, ApoE Alleles, and Alzheimer Disease: A Position Paper
Volume: 4 Issue: 2
Author(s): Caleb E. Finch and Todd E. Morgan
Affiliation:
Keywords: Alzheimer, aging, apoE, evolution, amyloid, infection, inflammation, CRP, IL-6
Abstract: Alzheimer disease (AD) includes inflammatory processes in the senile plaques and surrounding glia, with increased expression of acute phase proteins such as C-reactive protein (CRP) and IL-6. Increased IL-6 expression during normal brain aging suggests a link of age-related inflammation to the onset of AD during aging. Blood levels of CRP and IL-6 are also associated with higher risk of Alzheimer disease and cognitive decline during aging. Some infections are known to induce inflammation and amyloid deposits. For example, HIV induces the deposition of the same beta-amyloid as in Alzheimer disease. The ApoE4 allele may increase HIV-associated dementia, in addition to its well-known effect on accelerating the onset age of AD. Many other adverse effects of apoE4 are recognized, which suggested the hypothesis that apoE4 persists in human populations because of balancing selection (Charlesworth-Martin hypothesis). The apoE4 allele was acquired during human evolution and may have conferred initial advantages in pathogen resistance. As evidence for this hypothesis, apoE4 carriers have less severe liver damage during hepatitis C infections. As human lifespan lengthened and cognitive and cardiovascular health became more important, the apoE3 allele spread, while the E4 allele was maintained in all populations by balancing selection.
Export Options
About this article
Cite this article as:
Finch E. Caleb and Morgan E. Todd, Systemic Inflammation, Infection, ApoE Alleles, and Alzheimer Disease: A Position Paper, Current Alzheimer Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720507780362254
DOI https://dx.doi.org/10.2174/156720507780362254 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical, Genetic, and Neuroimaging Features of Early Onset Alzheimer Disease: The Challenges of Diagnosis and Treatment
Current Alzheimer Research The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy
Current Pharmaceutical Design Roles of TRAF6 in Central Nervous System
Current Neuropharmacology Anticoagulant Therapy in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets Intracerebral Hemorrhage and Diabetes Mellitus: Blood-Brain Barrier Disruption, Pathophysiology and Cognitive Impairments
CNS & Neurological Disorders - Drug Targets Memantine and Kynurenic Acid: Current Neuropharmacological Aspects
Current Neuropharmacology Molecular Mechanism of Autophagy: Its Role in the Therapy of Alzheimer’s Disease
Current Neuropharmacology Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence
Current Neuropharmacology Editorial:Advanced Methods of Biomedical Signal Processing for Early Detection of Alzheimer`s Disease
Current Alzheimer Research Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems
Current Drug Targets The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice
CNS & Neurological Disorders - Drug Targets Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia
Current Alzheimer Research Bivalent Ligands Derived from Huperzine A as Acetylcholinesterase Inhibitors
Current Topics in Medicinal Chemistry A Molecular Bridge: Connecting Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Editorial [Hot topic: Adenosine Receptor Ligands: Where Are We, and Where Are We Going? (Guest Editors: Tiziano Tuccinardi and Adriano Martinelli)]
Current Topics in Medicinal Chemistry <i>Nigella sativa</i> L., Supplementary Plant with Anticholinesterase Effect for Cognition Problems: A Kinetic Study
Current Aging Science Multiple Hormonal Dysregulation as Determinant of Low Physical Performance and Mobility in Older Persons
Current Pharmaceutical Design Astrocytes Exert and Control Immune Responses in the Brain
Current Immunology Reviews (Discontinued) Amyloid Deposition and Inflammation in APPswe/PS1dE9 Mouse Model of Alzheimers Disease
Current Alzheimer Research Treatment Options in Alzheimer´s Disease: The GABA Story
Current Pharmaceutical Design